A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events

A 63-year-old man with hepatitis C was treated with atezolizumab plus bevacizumab for unresectable diffuse hepatocellular carcinoma (HCC). After four cycles of atezolizumab plus bevacizumab, the diffuse HCC markedly shrank; however, he complained of general fatigue, loss of appetite, and slight loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Hidemi, Sawada, Koji, Hasebe, Takumu, Nakajima, Shunsuke, Sawada, Jun, Takiyama, Yuri, Takiyama, Yumi, Okumura, Toshikatsu, Fujiya, Mikihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790772/
https://www.ncbi.nlm.nih.gov/pubmed/35491133
http://dx.doi.org/10.2169/internalmedicine.9393-22
_version_ 1784859254445834240
author Hayashi, Hidemi
Sawada, Koji
Hasebe, Takumu
Nakajima, Shunsuke
Sawada, Jun
Takiyama, Yuri
Takiyama, Yumi
Okumura, Toshikatsu
Fujiya, Mikihiro
author_facet Hayashi, Hidemi
Sawada, Koji
Hasebe, Takumu
Nakajima, Shunsuke
Sawada, Jun
Takiyama, Yuri
Takiyama, Yumi
Okumura, Toshikatsu
Fujiya, Mikihiro
author_sort Hayashi, Hidemi
collection PubMed
description A 63-year-old man with hepatitis C was treated with atezolizumab plus bevacizumab for unresectable diffuse hepatocellular carcinoma (HCC). After four cycles of atezolizumab plus bevacizumab, the diffuse HCC markedly shrank; however, he complained of general fatigue, loss of appetite, and slight loss of muscle strength in the lower legs. He was diagnosed with isolated adrenocorticotropic hormone deficiency (IAD), hypothyroidism, and myopathy, suggesting multisystem immune-related adverse events (irAEs). After administration of hydrocortisone, the clinical symptoms rapidly disappeared. Patients with multisystem irAEs can have favorable outcomes; thus, to continue immune-checkpoint inhibitors therapy, a correct diagnosis and management of multisystem irAEs are important.
format Online
Article
Text
id pubmed-9790772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-97907722023-01-05 A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events Hayashi, Hidemi Sawada, Koji Hasebe, Takumu Nakajima, Shunsuke Sawada, Jun Takiyama, Yuri Takiyama, Yumi Okumura, Toshikatsu Fujiya, Mikihiro Intern Med Case Report A 63-year-old man with hepatitis C was treated with atezolizumab plus bevacizumab for unresectable diffuse hepatocellular carcinoma (HCC). After four cycles of atezolizumab plus bevacizumab, the diffuse HCC markedly shrank; however, he complained of general fatigue, loss of appetite, and slight loss of muscle strength in the lower legs. He was diagnosed with isolated adrenocorticotropic hormone deficiency (IAD), hypothyroidism, and myopathy, suggesting multisystem immune-related adverse events (irAEs). After administration of hydrocortisone, the clinical symptoms rapidly disappeared. Patients with multisystem irAEs can have favorable outcomes; thus, to continue immune-checkpoint inhibitors therapy, a correct diagnosis and management of multisystem irAEs are important. The Japanese Society of Internal Medicine 2022-04-30 2022-12-01 /pmc/articles/PMC9790772/ /pubmed/35491133 http://dx.doi.org/10.2169/internalmedicine.9393-22 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hayashi, Hidemi
Sawada, Koji
Hasebe, Takumu
Nakajima, Shunsuke
Sawada, Jun
Takiyama, Yuri
Takiyama, Yumi
Okumura, Toshikatsu
Fujiya, Mikihiro
A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
title A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
title_full A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
title_fullStr A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
title_full_unstemmed A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
title_short A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
title_sort successful case of hepatocellular carcinoma treated with atezolizumab plus bevacizumab with multisystem immune-related adverse events
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790772/
https://www.ncbi.nlm.nih.gov/pubmed/35491133
http://dx.doi.org/10.2169/internalmedicine.9393-22
work_keys_str_mv AT hayashihidemi asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT sawadakoji asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT hasebetakumu asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT nakajimashunsuke asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT sawadajun asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT takiyamayuri asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT takiyamayumi asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT okumuratoshikatsu asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT fujiyamikihiro asuccessfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT hayashihidemi successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT sawadakoji successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT hasebetakumu successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT nakajimashunsuke successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT sawadajun successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT takiyamayuri successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT takiyamayumi successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT okumuratoshikatsu successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents
AT fujiyamikihiro successfulcaseofhepatocellularcarcinomatreatedwithatezolizumabplusbevacizumabwithmultisystemimmunerelatedadverseevents

Ejemplares similares